. 2011 Jan 22;20(1):107–117. doi: 10.1007/s00520-010-1073-9

Table 1.

NCCN antiemesis guidelines[1]

Chemotherapy	Antiemetics
Acute CINV (day 1)
High risk	5HT₃-antagonist + dexamethasone + aprepitant
Moderate risk	5HT₃-antagonist + dexamethasone + aprepitant in selected patients^a
Low risk	dexamethasone or metoclopramide or prochlorperazine
Minimal risk	No antiemetics
Delayed CINV
High risk	Dexamethasone (days 2–4) + aprepitant (days 2–3) + lorazepam in selected patients
Moderate risk	Dexamethasone (days 2–4) + aprepitant if used on day 1 (days 2–3)^a or 5HT₃-antagonist (days 2–4) + lorazepam in selected patients
Low en minimal risk	No antiemetics

^aAprepitant should be added to dexamethasone and a 5-HT3 antagonist for patients receiving the combination of an anthracycline and cyclophosphamide and selected patients receiving other chemotherapies of moderate emetic risk (e.g., carboplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, methotrexate)